


## DOTW: Ubrelvy (Ubrogепant)



- Approved by the FDA on December 23, 2019 for treatment of acute migraine with or without aura
- First oral therapeutic of the calcitonin gene-related peptide (CGRP) receptor antagonist family
- Potent, highly selective, competitive CGRP receptor antagonist (inhibitory constant  $K_i = 0.067$  nmol/L)
- $IC_{50} = 0.08$  nmol/L for  $\alpha$ -CGRP-stimulated cycle AMP response in human CGRP receptor expressing HEK293
- Clinical studies show low to minimal risk of medication overuse headaches, cardiovascular risk, or hepatotoxicity, which are common side effects in other migraine therapeutics (e.g. triptans, earlier gepants)
- Ubrogепant was developed by Merck, but worldwide rights to small molecule CGRP receptor antagonists were bought by Allergan for \$250 million, development/commercial milestone payments, and double digit royalties

